Healthcare (Public Health)

This bill modifies the Public Health Service Act to simplify the process for reviewing biosimilar drugs, which are generic versions of existing biologic medicines. By removing a specific requirement and renumbering a related clause, the legislation aims to reduce regulatory hurdles for manufacturers seeking approval for these products. The change directly impacts pharmaceutical companies and the FDA, potentially allowing for a more efficient evaluation of biosimilars without altering the fundamental safety standards.

The Green New Deal for Health Act establishes a comprehensive federal framework to address the intersection of climate change and public health by creating new offices, expanding funding, and mandating specific actions across the health care sector. It directly affects hospitals, health care providers, medical manufacturers, health professions schools, and communities identified as environmentally or medically underserved. Key provisions include establishing an Office of Climate Change and Health Equity to develop a national strategic action plan, requiring hospitals to provide detailed notifications and mitigation plans before discontinuing services or closing, and offering grants to modernize medical facilities for climate resilience. The bill also mandates that the health care sector disclose climate risks associated with medical supplies, expands Medicare coverage for home resiliency services like heat pumps for vulnerable patients, and allocates billions in funding to train health workers on climate-related health risks. Additionally, the legislation creates a research initiative to study climate impacts on health and establishes requirements for green, zero-emission medical manufacturing and supply chains.

The ORTHO Act directs the Federal Trade Commission to create new rules requiring dentists to perform an in-person examination before providing most dental services or medical devices through teledentistry. This requirement includes exceptions for emergency care, approved public health programs, and specific orthodontic diagnoses that must still be confirmed by an in-person visit and review of X-rays before a patient begins using an appliance. Violations of these rules would be treated as unfair or deceptive practices, allowing both the FTC and state attorneys general to enforce the law through civil penalties and potential damages. The bill also clarifies that states retain the ability to adopt additional regulations that are consistent with these federal standards.

The Medicare-X Choice Act of 2026 creates a new public health plan called the Medicare Exchange health plan, which would be available to individuals and small groups starting in 2028. The bill establishes two dedicated funds to finance the plan's creation and technology updates, appropriating $1 billion each for fiscal year 2027. Under the plan, the government would set premiums to cover full costs, and reimbursement rates for doctors and hospitals would generally match current Medicare rates, with potential increases for rural areas. The legislation also requires health care providers who participate in traditional Medicare to also accept patients in this new plan, while prohibiting insurers from placing additional restrictions on enrollees. Additionally, the bill expands tax credits for people buying insurance, fixes the "family glitch" that currently limits subsidy eligibility for some workers, and authorizes the government to negotiate prices for prescription drugs.

The Secure Drug Supply Chain Act of 2026 aims to protect the U.S. pharmaceutical supply by preventing the importation of counterfeit or unsafe drugs from countries like China and others designated as adversarial. It requires drug manufacturers to report quarterly details about the origins of their active ingredients and key starting materials, specifically highlighting those sourced from China or other foreign countries of concern. The bill also strengthens enforcement by allowing the government to ban imports from facilities using forced labor or violating sanctions, and it mandates the destruction of refused drugs that pose significant public health risks. Additionally, the law establishes new reporting requirements to track supply chain vulnerabilities and directs the Health and Human Services Secretary to issue regulations and guidance to implement these measures.

This bill creates a new program to speed up the approval process for specific over-the-counter drugs that could offer significant public health benefits. Drug companies can request this "priority" status for new medications intended for conditions that currently require a prescription, provided the drugs are new or contain active ingredients never seen in nonprescription products. If approved, the FDA will assign senior staff and specialized teams to work closely with the companies, offering faster guidance and more efficient review schedules while maintaining the same safety and effectiveness standards. The program includes a requirement to publish a list of eligible health conditions and will expire in September 2032 unless renewed by Congress.

The Water Emergency and Technical Assistance Act of 2026 establishes a funding mechanism to help states and water treatment facilities respond to emergencies that pose a significant danger to public health, such as sewer overflows or cybersecurity incidents. Under this bill, the Environmental Protection Agency Administrator can provide grants and technical assistance for activities that prevent or mitigate health risks but would be too costly for ratepayers to fund on their own. The legislation authorizes $50 million annually from fiscal years 2027 through 2031 to support these emergency efforts and also increases the existing funding for drinking water emergencies during the same period.

The EBOLA Act directs the President to rejoin the World Health Organization within 30 days and immediately collaborate with the agency to address the ongoing Ebola outbreak in Central and Eastern Africa. This legislation authorizes funding to cover the financial obligations required to restore U.S. membership and to support global response efforts aimed at preventing the virus from spreading internationally. The bill is based on the finding that infectious disease outbreaks pose significant threats to national security and public health, and that participation in the WHO is essential for effective disease monitoring and coordination.

The Governors' Right to Inspect Act of 2026 allows state governors and designated public health officials to enter federal immigration detention facilities to check conditions related to health, safety, sanitation, and medical care. This authority applies to all U.S. detention centers, whether run directly by the government or by private contractors, and permits inspectors to review records and interview detainees who wish to speak privately. While the law grants access to inspect physical conditions, it explicitly prevents state officials from interfering with immigration enforcement, custody decisions, or the release of any detained individuals. Facility operators must cooperate with these inspections, and governors may submit their findings to Congress and the public, requiring a response from the Department of Homeland Security within 60 days.

This bill directs the Health Resources and Services Administration to help federally qualified health centers expand nutrition education and counseling services to patients. It allows the use of existing funds to support activities such as training healthcare providers, hiring dietitians, and creating culturally appropriate educational materials. The program specifically prioritizes health centers serving communities with high rates of diet-related chronic diseases and food insecurity. Additionally, the bill requires the government to submit annual reports to Congress on how these initiatives improve patient outcomes and workforce capabilities.